Unknown

Dataset Information

0

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenstrom macroglobulinemia.

ABSTRACT:

SUBMITTER: Othman J 

PROVIDER: S-EPMC5927990 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Waldenstrom macroglobulinemia treatment algorithm 2018.
| S-EPMC5928091 | biostudies-literature
Unknown Thalidomide and rituximab in Waldenstrom macroglobulinemia.
| S-EPMC2597120 | biostudies-literature
Unknown Management of Waldenstrom macroglobulinemia in 2020.
| S-EPMC7727571 | biostudies-literature
Unknown Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
| S-EPMC6363842 | biostudies-literature
Unknown Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
| S-EPMC7556127 | biostudies-literature
Unknown Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1.
| S-EPMC4406272 | biostudies-literature
Unknown microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.
| S-EPMC2938840 | biostudies-other
Unknown New developments in the management of Waldenstrom macroglobulinemia.
| S-EPMC5354523 | biostudies-literature
Unknown Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia.
| S-EPMC7484977 | biostudies-literature
Unknown Ibrutinib in Waldenstrom macroglobulinemia: latest evidence and clinical experience.
| S-EPMC4959643 | biostudies-literature